Unicycive Therapeutics Inc.

UNCY | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.77

-$0.03 (-0.63%)

At close: Sep 21, 2026, 4:00 PM ET

$4.77

$0 (0.00%)

Pre-market: Sep 22, 2026, 8:44 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Key Executives

Name	Position
Shalabh K. Gupta	Founder, Chairman, Chief Executive Officer & President
John W. Townsend	Chief Financial Officer
Douglas Jermasek	Executive Vice President of Corporate Strategy
Pramod Gupta	Executive Vice President of Pharmaceutical and Business Operations

Latest SEC Filings

Date	Type	Title
Aug 14, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Aug 14, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Aug 12, 2026	8-K	Current Report
Aug 12, 2026	10-Q	Quarterly Report
Jul 30, 2026	SC 13G	Statement of acquisition of beneficial ownership b...
Jul 28, 2026	4/A	[Amend] Filing
Jul 28, 2026	4/A	[Amend] Filing
Jul 08, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Jul 02, 2026	8-K	Current Report
Jun 22, 2026	DEFA14A	Filing

View All SEC Filings ➞

Unicycive Therapeutics Inc.

Country	United States
IPO Date	Jul 11, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	21
CEO	Shalabh K. Gupta

Contact Details

1975 West El Camino Real Mountain View, California 94040 United States

https://www.unicycive.com

650 351 4495

Stock Details

Ticker Symbol	UNCY
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001766140
CUSIP Number	90466Y202
ISIN Number	US90466Y2028
SIC Code	2834